Postbiotics: The Next Frontier in Microbiome Therapy
A Summary of Recent Clinical Evidence on Postbiotics, Including Extracellular Vesicles as Emerging Therapeutic Candidates
Specialist in probiotic microencapsulation, extracellular vesicles and gut microbiome biology
Introduction
The microbiome has emerged as a critical regulator of human health, influencing everything from gastrointestinal function to immune homeostasis and even neurological health. For years, probiotics—live beneficial bacteria—have dominated the conversation around microbiome-targeted therapies. However, a new paradigm is taking shape: postbiotics.
Unlike probiotics, postbiotics are preparations of inanimate microorganisms and/or their components that confer health benefits without requiring viability (Salminen et al., 2021). This distinction matters clinically: postbiotics offer superior stability, enhanced safety profiles for immunocompromised patients, and a more defined mechanism of action. As the field of microbiome therapeutics matures, postbiotics—including bacterial extracellular vesicles (EVs)—are emerging as the next frontier in precision microbiome therapy.
This article summarizes the most recent clinical trial evidence on postbiotics across multiple therapeutic areas and explores the promising role of probiotic-derived extracellular vesicles as next-generation postbiotic candidates.
What Are Postbiotics? A Clinical Definition
The International Scientific Association for Probiotics and Prebiotics (ISAPP) defines postbiotics as "a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host" (Salminen et al., 2021).
Important distinction: According to this definition, postbiotics are intact inactivated microbial cells or structural components thereof (such as cell wall fragments, lipoteichoic acid, or extracellular vesicles). Purified microbial metabolites—such as short-chain fatty acids (SCFAs), bacteriocins, or indole derivatives—are not considered postbiotics under the ISAPP definition, as they are metabolic products rather than microbial components (Salminen et al., 2021).
| Category | Examples | Clinical Relevance |
|---|---|---|
| Inactivated bacteria | Heat-killed Akkermansia muciniphila, Bifidobacterium bifidum | Improved metabolic parameters, IBS symptom relief (Depommier et al., 2019; Andresen et al., 2020) |
| Bacterial lysates | E. coli + Enterococcus faecalis lysate | Gut barrier protection, endotoxin translocation reduction |
| Extracellular vesicles | L. plantarum, L. casei EVs | Immunomodulation, gut-brain axis signaling (Hao et al., 2021; D'Antoni et al., 2025) |
| Cell wall components | Lipoteichoic acid, exopolysaccharides | Immune activation, cholesterol reduction |
Compared to probiotics, postbiotics offer distinct clinical advantages, including enhanced stability (no cold chain required), superior safety for immunocompromised patients, defined composition with consistent dosing, and efficacy unaffected by concomitant antibiotic use.
Recent Clinical Trial Evidence
1. Gut Health: Constipation
A landmark randomized, double-blind, placebo-controlled crossover trial evaluated the postbiotic Probio-Eco (fermented by Lacticaseibacillus paracasei Zhang, Lactiplantibacillus plantarum P-8, and Bifidobacterium lactis V9) in 110 adults with chronic constipation (Ma et al., 2025).
Key findings:
- •Significant increase in weekly complete spontaneous bowel movements (CSBMs) compared to placebo (19.1% improvement; p = 0.047)
- •Significant reduction in stool straining scores (30.5% improvement)
- •Modulation of gut microbiota and metabolites, including increased succinate, tryptophan derivatives, and SCFAs (note: SCFAs are microbial metabolites, not postbiotics under the ISAPP definition)
- •No serious adverse events; mild gastrointestinal symptoms were comparable to placebo
Clinical takeaway: Postbiotics represent a safe, well-tolerated option for chronic constipation management, with effects mediated through microbial components and associated metabolic changes.
2. Dermatology: Acne Vulgaris
A systematic review (33 studies, 2,112 patients) evaluated microbiome-modulating therapies for acne vulgaris, including postbiotics (Fadaee et al., 2026).
Key findings:
- •Postbiotics demonstrated the highest pooled mean total lesion reduction: −49.5%, compared to −45.2% for probiotics and −37.2% for prebiotics
- •Control groups (standard treatment alone) showed −37.0% reduction
- •Safety was favorable across all modalities with no serious adverse events
- •Treatment durations ranged from 4–25 weeks; postbiotics were primarily administered topically
Clinical takeaway: Postbiotics may enhance the efficacy of standard acne therapies, with lesion reductions exceeding those achieved with probiotics alone (Fadaee et al., 2026). Topical postbiotic formulations warrant further investigation as adjunctive treatments.
3. Oral Health: Dental Caries and Periodontal Disease
A comprehensive review of synbiotic and postbiotic supplements in oral health identified 17 relevant clinical studies (Twetman & Belstrøm, 2025).
Key findings:
- •Lozenges/tablets containing postbiotics reduced caries incidence in preschool and schoolchildren compared to standard preventive care
- •In adults with periodontitis, adjunctive postbiotic use enhanced outcomes of conventional scaling and root planing
- •Evidence was graded as low certainty, but consistently favorable
Clinical takeaway: Postbiotics may offer a sustainable, non-live alternative to probiotics in oral care products, with promising effects on biofilm modulation and caries prevention (Twetman & Belstrøm, 2025).
4. Liver Disease: Alcohol-Related Liver Fibrosis
The GALA-POSTBIO randomized controlled trial (Phase 2) investigated ReFerm®, an oat-based postbiotic fermented with Lactobacillus plantarum DSM 9843, in 56 patients with advanced alcohol-related liver disease (ALD) (Hansen et al., 2025).
Key findings:
- •Primary outcome (≥10% reduction in α-SMA) was not statistically significant (29% in postbiotic group vs. 14% in control)
- •However, secondary outcomes showed promise:
- –Reduced liver stiffness
- –Lower levels of fibrosis biomarker PRO-C3
- –Decreased circulating I-FABP (marker of gut barrier damage)
- •Multi-omics analyses suggested enhanced gut barrier function and hepatic regeneration without altering microbiome composition
Clinical takeaway: While the primary endpoint was not met, postbiotics targeting the gut-liver axis show mechanistic promise (Hansen et al., 2025). The approach—treating liver disease by restoring gut barrier integrity—represents a paradigm shift in hepatology.
5. Antibiotic-Induced Microbiome Injury
A pilot randomized controlled trial (32 patients) evaluated whether a fermentation-derived postbiotic could reduce antibiotic-induced microbiome injury during oral antibiotic treatment (Schluter et al., 2026).
Key findings:
- •Patients receiving postbiotic alongside antibiotics had 40% higher fecal bacterial alpha diversity (Inverse Simpson index) compared to placebo
- •Enrichment of health-associated obligate anaerobic Firmicutes, particularly Lachnospiraceae
- •Reduction in Escherichia/Shigella species (linked to pathogenicity and antibiotic resistance) persisted up to 10 days post-treatment
- •Treatment was well-tolerated
Clinical takeaway: Postbiotic co-administration during antibiotic therapy may mitigate antibiotic-induced microbiome injury and accelerate recovery of health-associated taxa (Schluter et al., 2026). This has implications for hospitalized patients, immunocompromised individuals, and those receiving prolonged antibiotic courses.
6. Respiratory Health: Gut-Lung Axis Modulation
A comprehensive review examined postbiotics and extracellular vesicles in respiratory infections and inflammation, including pneumonia, influenza, COVID-19, asthma, and cystic fibrosis (Fadaee et al., 2025).
Key mechanisms identified:
- •Epithelial barrier strengthening: Upregulation of tight junction proteins (claudin, occludin) in lung epithelium
- •Immunomodulation: Inhibition of NF-κB signaling; increased IL-10; decreased TNF-α, IL-6
- •Biofilm disruption: Postbiotics disrupt pathogenic biofilms in chronic respiratory conditions
- •Gut-lung axis effects: Systemic immune balance influenced by gut-derived postbiotic components
Clinical takeaway: Postbiotics offer a novel approach to respiratory health, particularly in chronic inflammatory conditions and recurrent infections (Fadaee et al., 2025). Their ability to modulate the gut-lung axis from the intestinal side presents opportunities for non-invasive interventions.
Extracellular Vesicles: A True Postbiotic Component
Among postbiotics, extracellular vesicles (EVs)—nanoscale particles secreted by probiotics—represent a particularly promising frontier. Under the ISAPP definition, EVs qualify as postbiotics because they are structural components of inanimate microorganisms (Salminen et al., 2021; Hao et al., 2021; D'Antoni et al., 2025).
What Are Probiotic-Derived EVs?
Probiotic-derived extracellular vesicles (P-EVs) are 20–200 nm lipid bilayer particles that carry bioactive cargo, including:
- •Proteins
- •Nucleic acids (DNA, RNA, miRNA)
- •Metabolites
Unlike live probiotics, P-EVs do not colonize or replicate. However, they retain the ability to signal to host cells, traverse biological barriers, and modulate immune responses (D'Antoni et al., 2025). As inanimate microbial components, they fall squarely within the ISAPP definition of postbiotics.
Emerging Therapeutic Applications
| Application | Mechanism | Evidence Level |
|---|---|---|
| Gut inflammation | L. plantarum EVs reduce body weight loss, bleeding, and colon shortening in colitis models | Preclinical (Hao et al., 2021) |
| Immunomodulation | P-EVs activate regulatory T cells; modulate Th1/Th2 balance | Preclinical (Hao et al., 2021) |
Why EVs Matter Clinically
P-EVs offer several advantages over both probiotics and other postbiotic preparations (D'Antoni et al., 2025):
- 1.Barrier crossing: EVs can cross the intestinal epithelium, opening possibilities for targeted delivery
- 2.Defined cargo: Unlike crude postbiotic preparations, EVs can be characterized and potentially standardized
- 3.Safety: Non-replicating, no risk of infection
Comparative Efficacy: Postbiotics vs. Probiotics
| Parameter | Probiotics | Postbiotics |
|---|---|---|
| Stability | Sensitive to temperature, pH, storage | Highly stable; no cold chain required |
| Safety | Risk of infection in immunocompromised | Safe for vulnerable populations |
| Mechanism | Requires colonization; strain-dependent | Defined components; direct host interaction (Salminen et al., 2021) |
| Dosing | Variable viability; CFU-dependent | Consistent; measurable active components |
| Antibiotic compatibility | Inactivated by antibiotics | Active during antibiotic treatment (Schluter et al., 2026) |
| Regulatory pathway | Complex; live organisms | Simpler; inanimate entities |
Safety Profile Across Clinical Trials
Across all studies reviewed—encompassing dermatology, gastroenterology, hepatology, and oral health—postbiotics demonstrated a favorable safety profile with no serious adverse events (Warp et al., 2026; Ma et al., 2025; Hansen et al., 2025; Twetman & Belstrøm, 2025).
Mild, self-limited adverse effects (when reported) included:
- •Bloating
- •Mild gastrointestinal discomfort
- •Isolated cases of nausea
No cases of bacteremia, infection, or systemic toxicity were reported, even in vulnerable populations.
Future Directions
The postbiotic field is advancing rapidly. Key areas for future research include:
- 1.Head-to-head trials: Comparative efficacy of postbiotics versus probiotics for specific indications
- 2.Standardized formulations: Defining active components and establishing dose-response relationships in line with the ISAPP definition (Salminen et al., 2021)
- 3.EV characterization: Developing standards for isolation, characterization, and dosing of P-EVs as postbiotic components (D'Antoni et al., 2025)
- 4.Mechanistic studies: Elucidating pathways by which specific postbiotic components exert clinical effects
- 5.Regulatory harmonization: Establishing clear pathways for postbiotic products as therapeutics (Salminen et al., 2021)
Clinical Implications for Healthcare Professionals
For clinicians considering postbiotic therapies, several principles emerge from the current evidence:
- •Postbiotics are not interchangeable with probiotics. Their mechanisms, stability, and safety profiles differ fundamentally (Salminen et al., 2021).
- •Postbiotics are microbial components, not purified metabolites. Under the ISAPP definition, postbiotics refer to inanimate microorganisms and their structural components—not SCFAs or other fermentation products (Salminen et al., 2021).
- •Consider postbiotics in vulnerable patients. Immunocompromised, critically ill, or hospitalized patients may benefit from the enhanced safety profile of inanimate microbial preparations.
- •Antibiotic co-administration is feasible. Unlike probiotics, postbiotics remain active during antibiotic therapy and may mitigate antibiotic-induced dysbiosis (Schluter et al., 2026).
- •Therapeutic areas are expanding. Beyond gastrointestinal health, postbiotics show promise in dermatology, hepatology, and respiratory medicine.
- •Extracellular vesicles represent the cutting edge. As true postbiotic components, P-EVs offer a path toward more targeted, defined, and potentially more potent therapies (Hao et al., 2021; D'Antoni et al., 2025).
Conclusion
Postbiotics—defined as inanimate microorganisms and/or their components—have emerged as a distinct, scientifically validated class of microbiome-targeted therapeutics. Recent clinical trials demonstrate their efficacy in constipation (Ma et al., 2025), acne vulgaris (Warp et al., 2026), periodontal disease (Twetman & Belstrøm, 2025), and antibiotic-induced microbiome injury (Schluter et al., 2026), with a consistently favorable safety profile.
Extracellular vesicles—the nanoscale structural components secreted by probiotic bacteria—represent the next frontier in postbiotic research. As true microbial components under the ISAPP definition, P-EVs offer a path toward more targeted, defined, and potentially more potent postbiotic therapies (Hao et al., 2021; D'Antoni et al., 2025).
For healthcare professionals, postbiotics offer a safe, stable, and increasingly evidence-based option for patients seeking microbiome-targeted interventions. As the field moves toward precision microbiome therapeutics, postbiotics—and particularly extracellular vesicles—are positioned to play a central role.
About the author
Cecilia L. D'Antoni holds a PhD in Biological Chemistry from the University of Buenos Aires, where she specialised in probiotic bacteria, extracellular vesicles and microencapsulation.
References
Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020 Jul;5(7):658-666. doi: 10.1016/S2468-1253(20)30056-X.
D'Antoni CL, Pourtalebi Jahromi L, Sana L, DomÃnguez Rubio AP, Dorfner M, Munkert J, Danzer H, Arnold P, Lebedev M, Zanin E, Pérez OE, Fuhrmann G. Membrane Vesicles from Lacticaseibacillus Casei BL23 Exhibit Antimicrobial Activity Against Escherichia coli and Immunostimulatory Effects on Human Peripheral Blood Mononuclear Cells. Adv Healthc Mater. 2025 Dec 5:e00548. doi: 10.1002/adhm.202500548.
Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019 Jul;25(7):1096-1103. doi: 10.1038/s41591-019-0495-2.
Fadaee M, Mahrooghi D, Lahouty M, Oskouei SA, Nezhadi J. Postbiotics and extracellular vesicles: Mechanisms of action and clinical promise in respiratory infections and inflammation. Infect Genet Evol. 2025 Nov;135:105837. doi: 10.1016/j.meegid.2025.105837.
Hansen, J.K., Israelsen, M., Nishijima, S. et al. The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial. Nat Commun 16, 5969 (2025). https://doi.org/10.1038/s41467-025-60755-9
Hao H, Zhang X, Tong L, Liu Q, Liang X, Bu Y, Gong P, Liu T, Zhang L, Xia Y, Ai L, Yi H. Effect of Extracellular Vesicles Derived From Lactobacillus plantarum Q7 on Gut Microbiota and Ulcerative Colitis in Mice. Front Immunol. 2021 Dec 2;12:777147. doi: 10.3389/fimmu.2021.777147.
Ma, T., Li, Y., Yang, N., Wang, H., Shi, X., Liu, Y., Jin, H., Kwok, L.-Y., Sun, Z., & Zhang, H. (2025). Efficacy of a postbiotic and its components in promoting colonic transit and alleviating chronic constipation in humans and mice. Cell Reports Medicine, 6(5), 102093. https://doi.org/10.1016/j.xcrm.2025.102093
Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., & Vinderola, G. (2021). The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nature Reviews Gastroenterology and Hepatology, 0123456789. https://doi.org/10.1038/s41575-021-00440-6
Schluter J, Jogia W, Matheis F, Ebina W, Sullivan AP, Gordon K, Cruz EFdl, Victory-Hays ME, Heinly MJ, Diefenbach CS, Kang UJ, Peled JU, Foster KR, Levitt A, McLaughlin E. A retrospectively registered pilot randomized controlled trial of postbiotic administration during antibiotic treatment increases microbiome diversity and enriches health-associated taxa. Infect Immun. 2026 Jan 13;94(1):e0039025. doi: 10.1128/iai.00390-25.
Twetman S, Belstrøm D. Effect of Synbiotic and Postbiotic Supplements on Dental Caries and Periodontal Diseases-A Comprehensive Review. Int J Environ Res Public Health. 2025 Jan 8;22(1):72. doi: 10.3390/ijerph22010072.
Warp PV, Bilik SM, Ferrari LM, Keri JE. Prebiotics, Probiotics, and Postbiotics for Acne Vulgaris: A Systematic Review. Dermatol Ther (Heidelb). 2026 Mar;16(3):1531-1550. doi: 10.1007/s13555-026-01659-4.
Disclaimer: This article is intended for healthcare professionals. It summarizes published clinical evidence and does not constitute medical advice. Clinicians should exercise their own professional judgment when considering postbiotic therapies.